(Source: Response Genetics Inc) July 8, 2013 Response Genetics, Inc. Announces Contract With Blue Cross and Blue Shield of Illinois LOS ANGELES, July 8, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has recently executed a provider contract with Blue Cross and Blue Shield of Illinois. Blue Cross and Blue Shield of Illinois has 7.4 million members, most of whom are located in the State of Illinois. With the execution of this agreement, oncologists and pathologists affiliated with this health plan now have the...
↧